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Abstract 
Approximately 25% of patients who are prescribed opioids for chronic pain misuse them, and 5-
10% develop an opioid use disorder. Although the neurobiological target of opioids is well known, 
the molecular mechanisms that are responsible for the development of addiction-like behaviors in 
some but not all individuals are poorly known. To address this issue, we used a unique outbred rat 
population (Heterogeneous Stock) that better models the behavioral and genetic diversity that is 
found in humans. We characterized individual differences in addiction-like behaviors using an 
Addiction Index that incorporates the key criteria of opioid use disorder: escalated intake, highly 
motivated responding, and hyperalgesia. Using in vitro electrophysiological recordings in the 
central nucleus of the amygdala (CeA), we found that rats with high addiction-like behaviors (HA) 
exhibited a significant increase in g-aminobutyric acid (GABA) transmission compared with rats 
with low addiction-like behaviors (LA) and naive rats. The superfusion of CeA slices with 
nociceptin/orphanin FQ peptide (N/OFQ; 500 nM), an endogenous opioid-like peptide, normalized 
GABA transmission in HA rats. Intra-CeA levels of N/OFQ were lower in HA rats than in LA 
rats. Intra-CeA infusions of N/OFQ (1 µg/site) reversed the escalation of oxycodone self-
administration in HA rats but not in LA rats. These results demonstrate that the downregulation of 
N/OFQ levels in the CeA may be responsible for hyper-GABAergic tone in the CeA that is 
observed in individuals who develop addiction-like behaviors. Based on these results, we 
hypothesize that small molecules that target the N/OFQ system might be useful for the treatment 
of opioid use disorder. 
 
  
  
Significance statement 
More than 2 million individuals in the United States currently have a substance use disorder that 
is related to prescription opioid pain relievers. We identified individual differences in oxycodone 
addiction-like behaviors in outbred heterogenous stock rats with high (HA) and low (LA) addiction 
like-behaviors. We found that the downregulation of nociceptin levels in the central nucleus of the 
amygdala (CeA) may be responsible for hyper-g-aminobutyric acid (GABA)ergic tone in the CeA 
that is observed in individuals who develop addiction-like behaviors. The development of small 
molecules that target the nociceptin system may have therapeutic efficacy for the treatment of 
opioid use disorder. 
  
  
Introduction 
 More than 2 million individuals in the United States currently have a substance use disorder 
that is related to prescription opioid pain relievers, including oxycodone (Oxycontin®, 
Roxycodone®, Oxecta®), and 500,000 are addicted to heroin (1). Over the past 15 years, the 
consumption of oxycodone increased ~500%, and opioid-related overdose deaths quadrupled (2, 
3). Although opioid medications effectively treat acute pain and help relieve chronic pain in some 
patients (4), the risk of addiction is a dilemma for healthcare providers who seek to relieve 
suffering while avoiding drug abuse and addiction. The misuse of and addiction to opioids—
including prescription pain relievers, heroin, and synthetic opioids—is a serious national health 
crisis that affects public health and social and economic welfare. Opioid addiction is a complex 
disease that is characterized by phenotypic heterogeneity. One of the reasons for the lack of novel 
drug treatments for opioid use disorder is that the mechanisms that are responsible for individual 
differences in the propensity to develop mild to severe opioid use disorder are unknown. The better 
characterization of addiction-like behaviors using advanced models of extended access to 
oxycodone self-administration (5, 6) in animal strains that exhibit large individual differences, 
such as heterogeneous stock (HS) rats (7, 8), may provide new insights into medication 
development.  
 Opioid misuse and addiction develop through a spiral of positive reinforcement (reward) 
and negative reinforcement (withdrawal) (9). The rewarding effects of opioids decrease because 
of tolerance, whereas the negative affective state increases because of neuroadaptive changes that 
are hypothesized to occur in the central nucleus of the amygdala (CeA) (10-14), among several 
other key brain regions, such as the bed nucleus of the stria terminalis, ventral tegmental area, 
habenula, and ventral striatum (9). The CeA is the major output region of the amygdala, mainly 
  
(95%) through long-range g-aminobutyric acid (GABA)ergic output neurons that express high 
levels of pro-stress and anti-stress peptides (11). 
 Nociceptin/orphanin FQ (N/OFQ; hereinafter referred to as nociceptin) is a 17-amino-acid 
opioid-like peptide that binds with high affinity to the N/OFQ opioid (NOP) receptor but has no 
affinity for µ-opioid (MOP), d-opioid (DOP), or k-opioid (KOP) receptors. Both nociceptin and 
NOP receptors are expressed in the amygdala (15). Behavioral and neurochemical studies have 
suggested an important role for the nociceptin NOP receptor system in opioid tolerance and reward 
(16-19), addiction to alcohol (20-24) and other drugs of abuse (20, 25-27), and the modulation of 
stress (28-30). Interestingly, nociceptin, despite being an opioid-like peptide, blocks opioid-
induced supraspinal analgesia (31) and morphine reward in the conditioned place preference 
paradigm (16, 17), morphine-induced dopamine release (32), and Fos expression in the nucleus 
accumbens (16). Additionally, pretreatment with a NOP receptor agonist modulated the subjective 
effects of oxycodone in mice (33). However, these previous studies were performed in 
nondependent animals with the goal of investigating the effect of nociceptin on the rewarding 
effects of opioids and elucidating the brain regions that are involved in the reward pathway (e.g., 
ventral tegmental area–nucleus accumbens pathway), and little was known about the role of 
nociceptin in opioid dependence and its role in brain pathways that are responsible for 
development of the negative affect state and motivation to take opioids during withdrawal. 
Interestingly, evidence of an association between two variants of the NOP receptor gene, OPRL1, 
and the vulnerability to opioid addiction in humans has been reported (34). 
 The present study investigated neuroadaptations of GABAergic and nociceptin 
transmission in the CeA in genetically diverse HS rats that exhibited high (HA) or low (LA) 
addiction-like behaviors after chronic (3 weeks) and extended (12 h/day) access to oxycodone self-
  
administration. We hypothesized that individual differences in addiction-like behaviors result from 
the dysregulation of GABAergic transmission by nociceptin in the CeA. 
 
Results 
Addiction Index: evaluation of individual differences in addiction-like behaviors 
 The timeline of the experiments is shown in Fig. 1A. The one-way analysis of variance 
(ANOVA) indicated that the animals significantly escalated their responses for oxycodone (F14,308 
= 9.934, p < 0.001; Fig. 1B). The Newman-Keuls post hoc test confirmed that significantly more 
active lever presses occurred from session 6 to session 9 (p < 0.05) and from session 10 to session 
14 (p < 0.001) compared with session 1. Inactive lever responding remained low for the entire 
duration of the experiment, illustrating strong lever discrimination. 
 After the escalation phase, a significant increase in mechanical hypersensitivity was 
observed in rats that escalated their oxycodone intake, with a significant decrease in pain 
thresholds in animals during acute withdrawal (t24 = 8.654, p < 0.001; Fig. 1C) compared with pain 
thresholds during their naive state. To evaluate addiction-like behaviors in individual rats, we used 
an Addiction Index that was adapted from Deroche-Gamonet et al. (35, 36), which considers 
various addiction-like behaviors: escalation of oxycodone intake under a fixed-ratio (FR) schedule 
of reinforcement, motivation to maintain responding under a progressive-ratio (PR) schedule of 
reinforcement, and withdrawal-induced hyperalgesia. To combine these different behavioral 
outputs, each measure was normalized into an index using its Z-score (Z = !"#$ ), where 𝜒 is the 
raw value, 𝜇 is the mean of the cohort, and 𝜎 is the standard deviation of the cohort. We thus 
obtained an FR Index, PR Index, and Pain Index (Fig. 1D). For the FR Index, the final values were 
obtained by calculating a Z-score that was the average of the Z-scores of the last 3 days of 
  
escalation. For the PR index, we calculated the Z-score of the breakpoint. For the Pain Index, the 
Z-score was calculated from the percent reduction of pain thresholds during withdrawal compared 
with naive baseline. Finally, we calculated the Addiction Index by averaging the Z-scores of the 
three dependent variables (FR Index, PR Index, and Pain Index; Fig 1E). Principal Component 
Analysis (PCA) was performed on the three addiction-like behaviors (escalation, motivation, and 
withdrawal-induced hyperalgesia) that comprise the Addiction Index to determine whether 
dimensionality could be reduced while maintaining variability. The PCA revealed only one 
component with an eigenvalue > 1, explaining 52% of variance and to which all three behaviors 
contributed in a valuable way (r = 0.63 to 0.83, Supporting Tables 1 and 2). This analysis supports 
the Addiction Index as a reflection of this first principal component and thus was a good approach 
to capture the variability in addiction-like behavior in one dimension. 
 We separated two groups of animals that were defined as high-addicted (HA; i.e., positive 
Addiction Index values) and low-addicted (LA; negative Addiction Index values) by a median 
split. As shown in Fig. 1D and E, significant differences in Z-scores were found for each individual 
variable after t-test comparisons when the groups were divided based on their Addiction Index: 
FR Index (t23 = 4.203, p < 0.001), PR Index (t23 = 3.721, p < 0.001), Pain Index (t23 = 2.304, p < 
0.05), Addiction Index (t23 = 5.778, p < 0.001). Analyses of the raw data showed that both HA and 
LA rats escalated their oxycodone self-administration (Fig. 1F). The two-way ANOVA, with 
group (HA vs. LA) as the between-subjects factor and time (sessions) as the within-subjects factor, 
revealed significant effects of group (F1,25 = 8.872, p < 0.01) and time (F13,325 = 8.933, p < 0.001) 
and a significant group ´ time interaction (F13,325 = 2.323, p < 0.01). The Newman-Keuls post hoc 
test showed that HA rats received significantly more drug infusions (rewards) on days 10-14 (p < 
0.001), whereas LA rats received significantly more rewards on days 11-14 (p < 0.05). Moreover, 
  
HA rats exhibited significantly higher oxycodone intake than LA rats on days 7-9 (p < 0.05) and 
days 10-14 (p < 0.001). The analysis of the PR data showed that HA rats reached higher 
breakpoints than LA rats (paired t-test: t23 = 3.721, p < 0.01; Fig. 1G). Finally, both HA and LA 
rats exhibited lower pain withdrawal thresholds compared with their pre-escalation baseline (LA: 
t12 = 5.68, p < 0.001; HA: t11 = 13.29, p < 0.001; paired t-tests), but HA rats exhibited an increase 
in hyperalgesia compared with LA rats (unpaired t-test: t23 = 2.429, p < 0.05; Fig. 1H). 
 
Cue-induced reinstatement 
We investigated the intensity of addiction-like behaviors in LA and HA rats by assessing 
their propensity to relapse to drug seeking (35). After training, escalation, and calculating the 
Addiction Index, 16 animals (n = 8 HA rats, n = 8 LA rats) were tested for cue-induced 
reinstatement (Fig. 2A). HA and LA rats extinguished active lever pressing behavior similarly 
(Fig. 2B). The two-way ANOVA, with group (HA vs. LA) as the between-subjects factor and time 
as the within-subjects factor, revealed a significant effect of time (F9,126 = 7.8, p < 0.0001) on active 
lever pressing but no significant effect of group (F1,14 = 3.84, p = 0.07) and no group ´ time 
interaction (F9,126 = 0.75, p = 0.66). For inactive lever presses, no significant effects of group (F1,14 
= 1.67, p = 0.22) or time (F9,126 = 1.40, p = 0.20) were observed, with no group ´ time interaction 
(F9,126 = 0.66, p = 0.75). For reinstatement (Fig. 2B), the two-way ANOVA, with group (HA vs. 
LA) as the between-subjects factor and experiment (average lever pressing during the last 3 days 
of extinction, lever pressing during SN presentation, and lever pressing during SD presentation) as 
the within-subjects factor, revealed significant effects of group (F1,14 = 4.60, p = 0.05) and 
experiment (F2,28 = 15.37, p < 0.0001) and a significant group ´ experiment interaction (F2,28 = 
4.22, p = 0.025). The Newman-Keuls post hoc test showed that reintroduction of the oxycodone-
  
discriminative cues (SD) but not neutral stimuli (SN) significantly reinstated extinguished 
oxycodone-seeking behavior in both groups (p < 0.001, vs. extinction for HA, and p < 0.05, vs. 
extinction for LA; Fig. 2B), but HA rats exhibited an increase in responding during SD presentation 
compared with LA rats (p < 0.001; Fig. 2B). A significant effect of experiment on inactive lever 
presses was observed (F2,28 = 9.24, p < 0.001), with no effect of group (F1,14 = 1.66, p = 0.22) and 
no group ´ experiment interaction (F2,28 = 1.38, p = 0.27). The reinstatement score for individual 
animals, which was calculated from the Z-score of their active lever presses during SD presentation, 
correlated with their Addiction Index (r = 0.56, p = 0.023; Fig 2C). 
 
HA rats have higher basal GABA release in the CeA 
 We next investigated whether the behavioral differences between HA and LA rats reflected 
differences at the cellular level (Fig. 3A). Output neurons in the CeA are mainly GABAergic; thus, 
we investigated GABAergic transmission by recording spontaneous inhibitory postsynaptic 
currents (sIPSCs) in CeA slices (Fig. 3B). The resting membrane potential of the neuronal sample 
was -64 ± 0.5 mV (n = 27). The input resistance was 256 ± 8 MΩ (n = 27). The holding potential 
was -67 ± 0.6 mV (n = 27). We found differences in baseline sIPSC frequencies in the CeA 
between HA rats, LA rats, and naive rats, confirmed by one-way ANOVA (F2,23 = 8.714, p < 0.01). 
The Newman-Keuls post hoc test indicated an increase in the baseline frequency of sIPSCs in HA 
rats compared with LA rats (p < 0.01) and naive rats (p < 0.05; Fig. 3C). No differences in sIPSC 
amplitude (F2,23 = 1.689, p > 0.05; Fig. 3D), sIPSC rise (F2,23 = 0.48, p > 0.05; Fig. 3E), or sIPSC 
decay (F2,23 = 0.58, p > 0.05; Fig. 3F) were observed between groups. 
 
Nociceptin-mediated modulation of GABAergic transmission in the CeA in HA rats vs. LA rats 
  
 We next investigated whether nociceptin prevents hyper-GABAergic transmission in the 
CeA. The acute (10 min) application of nociceptin (500 nM) (28) on CeA slices significantly 
decreased sIPSC frequencies compared with baseline frequencies in oxycodone-treated rats but 
not in naive rats (naive: t7 = 1.855, p > 0.05; LA: t7 = 3.998, p < 0.05; HA: t9 = 6.367, p < 0.01; 
Fig. 4A-C). The one-way ANOVA showed that the effect of nociceptin was more pronounced in 
HA rats (F2,23 = 4.415, p < 0.05) than in naive and LA rats. The Newman-Keuls post hoc test 
showed a significant difference in sIPSC frequency between HA and LA rats (p < 0.05; Fig. 4D). 
No differences in sIPSC amplitude were detected between groups upon the application of 
nociceptin (Fig. 4E). 
 
Nociceptin in the CeA selectively reduces oxycodone self-administration in HA rats 
 To further investigate the effects of nociceptin in the CeA on addiction-like behaviors, two 
cohorts of rats were trained to self-administer oxycodone and then underwent bilateral cannulation 
in the CeA for localized nociceptin administration (Fig. 5A). After recovery and reestablishing 
baseline self-administration in one cohort, nociceptin and vehicle were injected in a Latin-square 
design, and the effects of nociceptin on oxycodone self-administration were evaluated in HA and 
LA rats (n = 8 HA rats, n = 7 LA rats; Fig. 5B). The two-way ANOVA, with group (HA vs. LA) 
as the between-subjects factor and treatment as the within-subjects factor, revealed significant 
effects of group (F1,11 = 7.78, p < 0.05) and treatment (F1,11 = 15.68, p < 0.01) and a significant 
group ´ treatment interaction (F1,11 = 10.66, p < 0.01). The Newman-Keuls post hoc test showed 
that HA rats self-administered significantly more oxycodone compared with LA rats when the 
animals received vehicle (p < 0.01). Nociceptin administration selectively reduced oxycodone 
intake in HA rats (p < 0.01) but was ineffective in LA rats. The histological verification of cannula 
  
placements identified two animals with misplaced cannulas (Fig. 5C). Data from these two rats 
were excluded from the main data analysis. Importantly, the behavioral data from these two rats 
showed that the injection of nociceptin outside the CeA did not produce any behavioral effects, 
suggesting that the reduction of oxycodone intake was CeA-specific. 
In the second cohort, the effect of nociceptin on withdrawal-induced hyperalgesia was 
evaluated in HA and LA rats (n = 7 HA rats, n = 7 LA rats) that received intra-CeA injections of 
nociceptin or vehicle in a Latin-square design (Fig. 5D). The two-way ANOVA, with group (HA 
vs. LA) as the between-subjects factor and treatment as the within-subjects factor, revealed a 
significant effect of group (F1,12 = 9.095, p = 0.01) but no effect of treatment (F1,12 = 2.99, p = 0.1) 
and no group ´ treatment interaction (F1,12 = 0.067, p = 0.8). Nociceptin treatment showed only a 
nonsignificant trend toward a reduction of pain withdrawal thresholds in both groups. 
 
HA rats have low levels of nociceptin in the CeA  
 Oxycodone-dependent rats (n = 7 HA rats, n = 7 LA rats) were euthanized 12 h into 
withdrawal, and their brains were rapidly removed (Fig. 5A). Relative nociceptin levels were 
determined between HA and LA rats and compared with their naive littermates (Fig. 5E). The one-
way ANOVA showed a significant effect of group (F2,18 = 5.034, p = 0.02). The Newman-Keuls 
post hoc test showed that nociceptin levels significantly decreased in HA rats compared with naive 
rats (p = 0.02; Fig. 5F). The Z-score of individual nociceptin levels in the CeA correlated with 
individual animals’ Addiction Index (r = -0.62, p = 0.017, Fig. 5G). 
 
Discussion 
  
 The present study identified individual differences in oxycodone addiction-like behaviors 
in a population of genetically diverse HS rats with high (HA) and low (LA) addiction like-
behaviors. HA rats exhibited an increase in CeA GABAergic transmission. Nociceptin decreased 
CeA GABAergic transmission in oxycodone-dependent rats, with a more pronounced effect in HA 
rats. HA rats also exhibited lower levels of nociceptin in the CeA. Intra-CeA nociceptin 
administration reduced oxycodone self-administration selectively in HA rats, without affecting 
intake in LA rats. 
 A critical step in the identification of novel targets for medication development is the use 
of animal models that incorporate key behavioral endpoints that are used in the diagnosis of opioid 
use disorder in humans. Such an analysis should be performed in a genetically diverse outbred 
population of rodents to better mimic genetic diversity among humans. We used an animal model 
of extended access to oxycodone self-administration combined with advanced behavioral analysis 
of the transition from controlled to escalated oxycodone self-administration (5, 6) in outbred HS 
rats. We measured the escalation of oxycodone intake using an FR schedule of reinforcement and 
the motivation for oxycodone intake using a PR schedule of reinforcement (35, 37). We also 
longitudinally assessed mechanical pain thresholds to evaluate hyperalgesia during oxycodone 
withdrawal (38). This advanced behavioral analysis provided dependent measures that we used to 
calculate the Addiction Index and identify animals with high (HA) and low (LA) addiction-like 
behaviors. Importantly, both HA rats and LA rats developed oxycodone dependence, in which they 
both significantly escalated their oxycodone intake and exhibited lower pain thresholds during 
withdrawal. However, we found significant differences between HA and LA rats in all three 
behavioral measures. HA rats exhibited higher escalation of oxycodone intake, higher breakpoints 
on the PR schedule, and lower pain thresholds during withdrawal compared with LA rats (Fig. 1). 
  
A cue-induced reinstatement test was also performed in these rats. No difference in responding for 
the lever that was previously paired with oxycodone was observed between HA and LA rats during 
extinction, but HA rats were more vulnerable to cue-induced relapse than LA rats, which is another 
major criteria for opioid use disorder (Fig. 2). 
 We next investigated whether the behavioral differences between HA and LA rats reflected 
differences at the cellular level by examining withdrawal-induced neuroadaptations in the CeA 
during extended access to oxycodone self-administration. HA rats exhibited an increase in baseline 
spontaneous GABAergic transmission, suggesting an increase in tonic GABA levels in HA rats 
(Fig. 3). This is consistent with previous studies that reported CeA neuroadaptations after extended 
access to cocaine self-administration (39) and after chronic intermittent exposure to alcohol vapor 
(40, 41). The lack of an effect on sIPSC amplitude, rise, and decay suggests that the increase in 
sIPSC frequency mostly reflected an increase in GABA release rather than postsynaptic 
adaptation. Additionally, extended access to oxycodone self-administration altered the sensitivity 
of CeA GABAergic transmission in response to nociceptin. Indeed, the acute bath application of 
nociceptin (500 nM) on CeA slides significantly decreased sIPSC frequencies compared with 
baseline frequencies in oxycodone-exposed rats but not in naive rats. The lack of an effect of 
nociceptin in naive animals contrasts with previous findings (28, 42) but may be related to the 
different strains of rats that were used in these studies. However, the nociceptin-induced decreases 
in GABAergic transmission were significantly higher in HA rats than in LA rats. These results are 
similar to findings in alcohol-dependent rats, in which nociceptin decreased basal GABAergic 
transmission and blocked the CRF-induced increase in GABA release to a greater extent than in 
naive controls (42). In the present study, all of the electrophysiological recordings were performed 
in the medial part of the CeA (CeM) because this area is a major output region that has been 
  
repeatedly implicated in the addiction process (43). However, the laterocapsular CeA has been 
referred to as the nociceptive amygdala, and neuroadaptations may also have occurred in this 
region (44-46). Our results suggest a presynaptic effect on GABA release onto the recorded CeM 
neurons. The precise location of the GABA-releasing neurons is unknown but may have originated 
from laterocapsular CeA or local CeM GABA neurons. This should be investigated in future 
studies. 
This mechanism was then confirmed in vivo. Significantly lower levels of nociceptin were 
detected by Western blot in the CeA in HA rats compared with naive rats. The restoration of 
nociceptin levels by site-specific microinjections of nociceptin in the CeA before the self-
administration session selectively reduced operant responding for oxycodone in HA rats (Fig. 5), 
without affecting oxycodone intake in LA rats. Intra-CeA nociceptin administration did not 
selectively reduce withdrawal-induced hyperalgesia in HA rats. This may indicate that withdrawal-
induced hyperalgesia was regulated by a different pathway.  
In summary, the present study found that the CeA nociceptin-GABA system is involved in 
the transition from controlled to escalated oxycodone intake. We hypothesize that high oxycodone 
intake in HA rats may lead to downregulation of the nociceptin system in the CeA and 
consequently the upregulation of CeA GABAergic transmission, which in turn may promote 
addiction-like behaviors. The disinhibition of GABAergic transmission in the CeA was normalized 
by the exogenous application of nociceptin. Intra-CeA nociceptin administration also attenuated 
addiction-like behaviors in HA rats. These results are consistent with a previous study in alcohol-
dependent animals (42) and suggest that the dysregulation of nociceptin may be a critical step in 
the transition to addiction-like behaviors. These findings suggest that the nociceptin system may 
be a promising target for the treatment of opioid use disorder. The direct effects of oxycodone on 
  
nociceptin and associations with the underlying diverse individual genotype of HS rats will be the 
topic of future genome-wide association studies. 
  
Materials and Methods 
Animals 
 Male HS rats were created to have as much genetic diversity as possible at the National 
Institutes of Health in the 1980s by outbreeding eight inbred rat strains (ACI/N, BN/SsN, BUF/N, 
F344/N, M520/N, MR/N, WKY/N, and WN/N) (7). The HS rats (n = 50) were provided by Dr. 
Leah Solberg Woods (Medical College of Wisconsin, now at Wake Forest University School of 
Medicine). The animals were housed two per cage on a reverse 12 h/12 h light/dark cycle (lights 
off at 8:00 AM) in a temperature (20-22°C) and humidity (45-55%) controlled vivarium with ad 
libitum access to tap water and food pellets (PJ Noyes Company, Lancaster, NH, USA). All of the 
procedures were conducted in strict adherence to the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use 
Committee of The Scripps Research Institute. At the time of testing, the rats’ body weights ranged 
between 350 and 400 g. 
 
Intravenous catheterization and intracranial surgery 
 The animals were anesthetized by isoflurane inhalation, and intravenous catheters were 
aseptically inserted in the right jugular vein using a modified version of a procedure that was 
described previously (47, 48). The vein was punctured with a 22-gauge needle, and the tubing was 
inserted and secured inside the vein by tying the vein with suture thread. The catheter assembly 
consisted of an 18 cm length of Micro-Renathane tubing (0.023 inch inner diameter, 0.037 inch 
  
outer diameter; Braintree Scientific, Braintree, MA, USA) that was attached to a guide cannula 
(Plastics One, Roanoke, VA, USA). The guide cannula was bent at a near right angle, embedded 
in dental acrylic, and anchored with mesh (2 cm square). The catheter exited through a small 
incision on the back, and the base was sealed with a small plastic cap and metal cover cap. This 
design helped maintain the catheter base sterile and protected. The catheters were flushed daily 
with heparinized saline (10 U/ml of heparin sodium; American Pharmaceutical Partners, 
Schaumburg, IL, USA) in 0.9% bacteriostatic sodium chloride (Hospira, Lake Forest, IL, USA) 
that contained 20 mg/0.2 ml of the antibiotic Timentin (GlaxoSmithKline). 
 A subset of the animals that received intra-CeA injections for behavioral analysis 
underwent stereotaxic surgery. To reach the CeA, guide cannulas were bilaterally implanted using 
the following coordinates with reference to bregma: anterior/posterior, -2.6 mm; medial/lateral, 
±4.2 mm; dorsal/ventral, -6.1 mm. The drug infusion was performed using a stainless-steel injector 
that protruded 2 mm from the guide cannula into the CeA. The animals were allowed to recover 
for 1 week after surgery. 
 
Drugs 
 Oxycodone (Sigma Aldrich, St. Louis, MO) was dissolved in 0.9% sodium chloride 
(Hospira, Lake Forest, IL, USA) and administered at a dose 150 µg/0.1 ml/kg. For the intracranial 
injections, nociceptin (Tocris, Minneapolis, MN, USA) was dissolved in 0.9% sodium chloride 
and injected bilaterally in the CeA at a concentration of 1 μg/0.5 μl/site. For electrophysiology, 
nociceptin (500 nmol/ml) was dissolved in the superfusate with the glutamate receptor blockers 
6-cyano-7-nitroquinoxaline-2,3-dione (CNQX; 10 µM) and DL-2-amino-5-phosphonovalerate 
(APV; 30 µM) and the GABAB receptor antagonist CGP55845A (1 µM). 
  
 
Operant training 
 Self-administration was performed in operant conditioning chambers (Med Associates, St. 
Albans, VT, USA) that were enclosed in sound-attenuating, ventilated environmental cubicles. 
The front door and back wall of the chambers were constructed of transparent plastic, and the other 
walls were opaque metal. Each chamber was equipped with two retractable levers that were located 
on the front panel. Oxycodone was delivered through plastic catheter tubing that was connected to 
an infusion pump. The infusion pump and a cue light were activated by responses on the right 
(active) lever. Responses on the left (inactive) lever were recorded but did not have any scheduled 
consequences. Activation of the pump resulted in the delivery of 0.1 ml of the fluid. A computer 
controlled fluid delivery and behavioral data recording. 
 
Oxycodone self-administration 
 Each session was initiated by the extension of two retractable levers into the operant 
chamber (29 cm × 24 cm × 19.5 cm; Med Associates, St. Albans, VT, USA). Responses on the 
right active lever were reinforced on an FR1 schedule by intravenous (IV) oxycodone (150 
µg/0.1 ml/kg/infusion) administration that was infused over 6 s followed by a 20 s timeout 
(TO20 s) period that was signaled by the illumination of a cue light above the active lever for 
14 days in 12-h daily sessions (5 sessions/week). Responses on the left inactive lever were 
recorded but had no scheduled consequences. On day 15, the rats were tested on a PR schedule 
of reinforcement, in which the response requirements for receiving a single reinforcement 
increased according to the following equation: [5e(injection number ´ 0.2)] − 5. This resulted in the 
following progression of response requirements: 1, 1, 2, 2, 3, 3, 4, 4, 6, 6, 8, 8, 10, 11, 12, 13, 14, 
  
15, 16, 17, etc. (+1) until 50, 60, 70, 80. 90, 100. The breakpoint was defined as the last ratio 
attained by the rat prior to a 60 min period during which a ratio was not completed. 
 
Mechanical nociceptive von Frey test 
 Hindpaw withdrawal thresholds were determined using von Frey filaments, ranging from 
3.63 to 125.89 g. A test session began after 10 min of habituation to the testing environment. A 
series of von Frey filaments was applied from below the wire mesh to the central region of the 
plantar surface of the left hindpaw in ascending order, beginning with the smallest filament (3.63 
g). The filament was applied until buckling of the hair occurred, and it remained in place for 
approximately 2 s. A sudden withdrawal of the hindpaw indicated a positive response. The 
stimulus was incrementally increased until a positive response was observed and then decreased 
until a negative response was observed to determine a pattern of responses to apply to the statistical 
method of Dixon (49). The 50% paw withdrawal threshold was determined by the formula Xf + 
kδ, where Xf is the last von Frey filament applied, k is the Dixon value that corresponded to the 
response pattern, and δ is the mean difference between stimuli. Once the threshold was determined 
for the left hindpaw, the same testing procedure was repeated for the right hindpaw after 5 min. 
Paw withdrawal thresholds were recorded before beginning the oxycodone self-administration 
sessions (i.e., when the animal was still naive to oxycodone) and after the last self-administration 
session (i.e., the morning of day 15, 12 h into withdrawal, immediately before PR testing). Paw 
withdrawal thresholds were also recorded for one cohort (n = 14) 10 min after the intra-CeA 
injection of nociceptin or saline (12 h after the last self-administration session). 
 
Cue-induced reinstatement 
  
Once the escalation of oxycodone self-administration was established and after the rats 
were characterized as HA or LA, one cohort of male HS rats (n = 14) underwent 10 additional 12-
h self-administration sessions in the presence of an intermittent tone that served as a 
contextual/discriminative stimulus (SD) that signaled availability of the reinforcer throughout the 
session. Following completion of the training procedure, the rats underwent daily 2-h extinction 
sessions, in which responses on the previously active lever had no programmed consequences (i.e., 
no oxycodone delivery and no light or sound cue presentation). This phase lasted until responding 
was extinguished (< 10 responses per session for 3 consecutive days). Twenty-four hours after the 
last extinction session, all of the rats were presented with a neutral stimulus (SN) in a 2-h session 
to control for specificity of the SD to reinstate extinguished oxycodone-seeking behavior. During 
the SN session, continuous 70 dB white noise and illumination of a 2.8 W house light that was 
located at the top of the chamber’s front panel signaled non-availability of the reinforcer. The next 
day, the rats were presented with the light and sound SD. 
 
Electrophysiology 
 Slices of the CeA were prepared from naive and oxycodone-dependent (HA and LA) 
rats (n = 15 rats total, n = 5/group). The naive rats were age-matched to the rats that were used 
in the behavioral experiments. Sham IV surgery was performed to equalize post-surgical stress 
in both groups. The rats were deeply anesthetized with isoflurane, and brains were rapidly 
removed and placed in oxygenated (95% O2, 5% CO2) ice-cold cutting solution that contained 
206 mM sucrose, 2.5 mM KCl, 1.2 mM NaH2PO4, 7 mM MgCl2, 0.5 mM CaCl2, 26 mM 
NaHCO3, 5 mM glucose, and 5 mM HEPES. Transverse slices (300 μm thick) were cut on a 
Vibratome (Leica VT1000S, Leica Microsystems, Buffalo Grove, IL, USA) and transferred to 
  
oxygenated artificial cerebrospinal fluid (aCSF) that contained 130 mM NaCl, 2.5 mM KCl, 
1.2 mM NaH2PO4, 2.0 mM MgSO4·7H2O, 2.0 mM CaCl2, 26 mM NaHCO3, and 10 mM 
glucose. The slices were first incubated for 30 min at 35°C and then kept at room temperature 
for the remainder of the experiment. Individual slices were transferred to a recording chamber 
that was mounted on the stage of an upright microscope (Olympus BX50WI). The slices were 
continuously perfused with oxygenated aCSF at a rate of 2-3 ml/min. Neurons were visualized 
with a 60´ water immersion objective (Olympus), infrared differential interference contrast 
optics, and a charge-coupled device camera (EXi Blue, QImaging, Surrey, Canada). Whole-cell 
recordings were performed using a Multiclamp 700B amplifier (10 kHz sampling rate, 10 kHz 
low-pass filter) and Digidata 1440A and pClamp 10 software (Molecular Devices, Sunnyvale, 
CA, USA). Patch pipettes (4-7 MΩ) were pulled from borosilicate glass (Warner Instruments, 
Hamden, CT, USA) and filled with 70 mM KMeSO4, 55 mM KCl, 10 mM NaCl, 2 mM MgCl2, 
10 mM HEPES, 2 mM Na-ATP, and 0.2 mM Na-GTP. Liquid junction potential corrections 
were performed offline. Pharmacologically isolated sIPSCs were recorded in the presence of 
the glutamate receptor blockers CNQX and APV and the GABAB receptor antagonist CGP55845. 
Experiments with a series resistance of > 15 MΩ or > 20% change in series resistance were 
excluded from the final dataset. The frequency, amplitude, and kinetics of sIPSCs were 
analyzed using semi-automated threshold-based mini detection software (MiniAnalysis, 
Synaptosoft, Fort Lee, NJ, USA) and visually confirmed. 
 
Effect of intra-CeA nociceptin on oxycodone self-administration and withdrawal-induced 
hyperalgesia 
 Once the escalation of oxycodone self-administration was established, the animals (n = 15) 
  
underwent stereotaxic surgery for bilateral cannula implantation in the CeA. After 1 week of post-
surgical recovery, the rats were returned to the self-administration chambers to restore their 
oxycodone self-administration within 10% of previous baseline levels. At this point, treatment 
began. One cohort of rats received bilateral injections of nociceptin (1 μg/0.5 μl/site) or vehicle 5 
min before beginning the self-administration session in a counterbalanced order. A session of 
baseline oxycodone self-administration was performed between the two rounds of the Latin-square 
design. At the end of the experiments, the animals were re-baselined for oxycodone self-
administration and euthanized 4 days later for histology and Western blot analysis. 
After cannulation surgery, recovery, and re-baselining, another cohort of rats (n = 16) 
received bilateral injections of nociceptin (1 μg/0.5 μl/site) or vehicle 10 min before testing 
hyperalgesia using the mechanical nociceptive von Frey test 12 h into withdrawal (i.e., when the 
animal usually starts a session). A session of baseline oxycodone self-administration was 
performed between the two rounds of the Latin-square design. At the end of the experiments, the 
animals were re-baselined for oxycodone self-administration and euthanized the next day for 
Western blot analysis. 
 
Western blot 
 The rats were euthanized by decapitation 12 h into withdrawal (i.e., the time point that 
corresponded to initiation of the daily self-administration sessions). The brains were rapidly 
removed, snap frozen, and entirely sliced (300-µm-thick slices). The CeA was dissected by 
punching (16 gauge needle), and the tissue was kept frozen until the analysis. The samples (1 
punch/20 µl) were homogenized in cold RIPA lysis buffer (25 mM Tris-HCl [pH 7.6], 150 mM 
NaCl, 1% Triton X-100, 1% sodium deoxycholate, and 0.1% sodium dodecyl sulfate [SDS]) that 
  
contained Halt protease and phosphatase inhibitor cocktail (catalog no. 78441, Thermo Fisher 
Scientific). The homogenates were centrifuged at 10,000 ´ g for 10 min at 4°C, and the protein 
concentration of the supernatant was determined using the Pierce PCA protein assay (catalog no. 
23227, Thermo Fisher Scientific). The samples (15 µl + 5 µl 4´ Laemmli sample buffer with 2-
mercaptoethanol, Bio-Rad) were heated at 95°C for 5 min and loaded on a 4-15% Mini-PROTEAN 
TGX Stain-Free Precast Gel (Bio-Rad) with 1´ running buffer (25 mM Tris, 192 mM glycine, 
0.1% SDS). Electrophoretic separation was performed on gel at 200 V for 30 min, which was then 
transferred to a 0.2 µm nitrocellulose membrane (Bio-Rad) by wet transfer at 25 V for 45 min. 
After transfer, the membrane was blocked with 5% milk in 0.05% Tween-20 in PBS (PBST). 
Immunoblot analysis was performed by overnight incubation at 4°C with primary antibodies for 
prepronociceptin (1:500, catalog no. NB100-1619, Novus Biologicals) and b-tubulin (1:1000, 
catalog no. NB600-936, Novus Biologicals) in 3% bovine serum albumin in PBST and secondary 
antibodies conjugated to horseradish peroxidase (rabbit, 1:10000, Cell Signaling Technology) in 
5% milk in PBST at room temperature for 45 min. Antigen-antibody complexes were detected by 
chemiluminescence using SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Scientific) and analyzed using a ChemiDoc MP (Bio-Rad) with Image Lab and ImageJ software. 
Prepronociceptin band intensities were normalized to b-tubulin band intensities to account for 
sample differences and are expressed relative to one of the samples from the naive group that was 
loaded on the same blot to account for differences in transfer efficiency between blots. 
 
Statistical analysis 
 The self-administration data were analyzed using repeated-measures ANOVA of the 
number of infusions that were earned during the escalation interval. Data from the mechanical 
  
nociception von Frey test during withdrawal were analyzed using Student’s t-test by comparing 
the withdrawal results with baselines during the animals’ naive state or comparing the HA and LA 
groups. Data from the cue-induced reinstatement and intra-CeA nociceptin experiments were 
analyzed using mixed factorial ANOVA, with group as the between-subjects factor and treatment 
as the within-subjects factor. Significant main effects were followed by the Newman-Keuls 
multiple-comparison post hoc test. Locally evoked IPSP amplitudes were analyzed using Clampfit 
10 software (Molecular Devices, Sunnyvale, CA, USA). The electrophysiological data were 
analyzed using t-tests or ANOVAs followed by the Newman-Keuls post hoc test when appropriate. 
Nociceptin levels between groups were analyzed using one-way ANOVA. Correlation analysis 
was performed by calculating Pearson correlation coefficients. For the Principal Component 
Analysis, three variables were considered: FR (measured as the average of number of rewards in 
the last 3 days), PR (measured as breakpoints during the PR schedule), and pain thresholds 
(measured as hyperalgesia during withdrawal). The principal component was selected according 
to an eigenvalue > 1 (see Supporting Table 1). The data are expressed as the mean ± SEM. In cases 
of ≤ 10 data points, individual data points are represented in the graphs. The statistical analyses 
were performed using GraphPad Prism, SPSS, and Statistica 7 software. Values of p < 0.05 were 
considered statistically significant. 
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Figure Legends 
Figure 1. Development of oxycodone dependence in two distinct populations of HS rats identified 
by the Addiction Index. (A) Schematic timeline of the experiments. (B) Escalation of oxycodone 
intake in HS rats. *p < 0.05, ***p < 0.01, vs. day 1. (C) Oxycodone withdrawal-induced 
hyperalgesia in HS rats. Bars represent the paw withdrawal threshold. ***p < 0.01, vs. baseline. 
(D) Z-scores for FR Index, PR Index, and Pain Index in LA rats (light blue) and HA rats (dark 
blue). *p < 0.05, ***p < 0.001, vs. LA. (E) Addiction Index in LA rats (light blue) and HA rats 
(dark blue). ***p < 0.001, vs. LA. (F) Escalation of oxycodone intake in HA and LA rats. *p < 
0.05, ***p < 0.001, vs. day 1; #p < 0.05, ###p < 0.001, vs. LA. (G) Oxycodone self-administration 
on a progressive-ratio schedule of reinforcement in HA and LA rats. **p < 0.01, vs. LA. (H) 
Oxycodone withdrawal-induced hyperalgesia in HA and LA rats. ***p < 0.001, vs. baseline; #p < 
0.05, vs. LA. The dotted line indicates the naive baseline threshold. 
 
Figure 2. Extinction and cue-induced reinstatement in HA and LA rats. (A) Schematic timeline 
of the experiments. (B) HA rats exhibited significant reinstatement of oxycodone intake 
compared with LA rats. The figure shows the baselines at the end of the self-administration 
phase (SA), lever pressing during extinction, and responses during the neutral stimulus (SN) 
session and contextual/discriminative stimulus (SD) session. ***p < 0.001, *p < 0.05, vs. 
Extinction; ##p < 0.001, vs. LA (n = 16 [n = 8/group]). (C) Correlation between Addiction Index 
and Z-score of the number of active lever presses during cue-induced reinstatement. *p < 0.05.  
 
Figure 3. HA rats exhibited an increase in GABAergic transmission in the CeA. (A) Schematic 
timeline of the experiments. (B) Central nucleus of the amygdala slice that shows placement of the 
  
recording electrode (infrared optics, 4´ objective). (C) HA rats exhibited an increase in sIPSC 
frequency compared with naive rats (*p < 0.05) and LA rats (**p < 0.01). No differences were 
observed in (D) sIPSC amplitude, (E) sIPSC rise, or (F) sIPSC decay. 
 
Figure 4. Nociceptin decreased GABAergic transmission in CeA neurons in oxycodone-
dependent rats. (A) (Left) Nociceptin did not significantly affect sIPSC frequency in naive rats. 
(Right) Representative whole-cell recordings and the effect of nociceptin on sIPSCs in naive rats. 
(B) (Left) Nociceptin reduced sIPSC frequency in LA rats (p < 0.05). (Right) Representative 
whole-cell recordings and the effect of 500 nM nociceptin on sIPSCs in LA rats. (C) (Left) 
Nociceptin reduced sIPSC frequency in HA rats. (Right) Representative whole-cell recordings 
and the effect of nociceptin on sIPSCs in HA rats. (D) Nociceptin more effectively reduced 
GABAergic transmission in HA rats than in LA rats. *p < 0.05, **p < 0.01, vs. baseline; #p < 
0.05, vs. LA rats. (E) Nociceptin did not affect the sIPSC amplitude in any of the three groups. 
 
Figure 5. Intra-CeA nociceptin administration reversed the escalation of oxycodone intake 
selectively in HA rats. (A) Schematic timeline of the experiments. Two cohorts underwent this 
procedure: one cohort was tested for the effect of intra-CeA nociceptin administration on self-
administration, and the other cohort was tested for the effect of intra-CeA nociceptin 
administration on pain thresholds. (B) Effect of intra-CeA nociceptin administration on 
oxycodone self-administration in HA and LA rats. *p < 0.05, vs. vehicle; ##p < 0.01, vs. HA rats. 
Red triangles represent data from animals with cannula misplacements. (C) Schematic diagram 
of intra-CeA cannula placements for the self-administration experiment (black dots) and pain 
threshold experiment (blue dots). (D) Effect of intra-CeA nociceptin administration on 
  
oxycodone withdrawal-induced hyperalgesia in HA and LA rats. The dotted line indicates the 
naive baseline threshold. n = 13 (n = 6-7/group). (E) Immunoluminescent Western blots that 
show nociceptin levels in naive, LA, and HA rats. n = 21 (n = 7/group). (F) Western blot 
revealed a significant decrease in nociceptin levels (internally normalized to tubulin and a naive 
rat on the blot) in HA rats compared with naive rats. HA rats exhibited a significant decrease in 
the normalized signal intensity of nociceptin compared with naive rats. *p = 0.02. (G) 
Correlation between Addiction Index and the Z-score of nociceptin levels in the CeA. *p < 0.02. 
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